menu
    • menu
    [{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ezogabine","moa":"KCNQ","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Xenon Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Xenon Pharmaceuticals"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Ezogabine","moa":"KCNQ","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Jefferies"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"NBI-921352","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":1.78,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"NBI-921352","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KCNQ potassium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XEN1101","moa":"KV7 potassium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"XEN1101","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Pharmaceuticals Inc \/ J.P. Morgan"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"XEN1101","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Xenon Pharmaceuticals Inc","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Xenon Pharmaceuticals Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Xenon Pharmaceuticals Inc

    Menu

    Xenon Pharmaceuticals Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of t...

                            Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

                            Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2023

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Proposed Public Offering

                            Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2023

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $225.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101...

                            Details : XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NBI-921352

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Recipient : Neurocrine Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences

                            Details : NBI-921352, an investigational, selective sodium channel 1.6 inhibitor (Nav1.6) currently under development in adult patients with focal onset seizures (FOS), failed to demonstrate meaningful reduction in seizure frequency.

                            Brand Name : NBI-921352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 09, 2023

                            Lead Product(s) : NBI-921352

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Recipient : Neurocrine Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in...

                            Details : XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

                            Details : New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2022

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

                            Details : The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as a Treatment for Ma...

                            Details : XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when co...

                            Brand Name : XEN1101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 03, 2022

                            Lead Product(s) : XEN1101

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed

                            Xenon Pharmaceuticals Inc

                            Canada arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NBI-921352

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Mi...

                            Details : Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.

                            Brand Name : NBI-921352

                            Molecule Type : Small molecule

                            Upfront Cash : $6.7 million

                            January 12, 2022

                            Lead Product(s) : NBI-921352

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Neurocrine Biosciences

                            Deal Size : $15.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth